1 nts (74%) continued in remission during this
median follow-up period.
2 sentation was treated with steroids (n = 30;
median follow-up period,
29.5 months), surgical resectio
3 iod, 58 months), or was conservative (n = 5;
median follow-up period,
35 months).
4 mean [SD] follow-up period, 8.1 [8.3] years;
median follow-up period,
4.3 [interquartile range [IQR],
5 mean [SD] follow-up period, 8.6 [8.9] years;
median follow-up period,
4.4 [IQR, 2.4-5.4] years) were
6 No patients were censored before 1 year (
median follow-up period 438 days, interquartile range 17
7 d, 29.5 months), surgical resection (n = 18;
median follow-up period,
58 months), or was conservative
8 tory drugs remain in steroid-free remission (
median follow-up period,
6 months).
9 ific survival, and recurrence-free survival (
median follow-up period,
70.8 months) were not statistic
10 During the 91-month
median follow-up period,
843 patients died (256 from car
11 ted liver transplantation from 1998 to 2009 (
median follow-up period,
89 months).
12 355 patients had at least 1 follow-up visit (
median follow-up period:
9.6 months).
13 The
median follow-up period after radioembolization was 38 m
14 Median follow-up period for AF onset was 11.6 years, and
15 In this report, we extend the
median follow-up period for patient and graft survival t
16 The
median follow-up period for patients who underwent compl
17 Median follow-up periods for the DCF (n = 409), fludarab
18 Over a 15-month
median follow-up period,
HI LLT use increased by 1.5%.
19 With nearly 15 years
median follow-up periods,
however, these data should be
20 WL of which 371 (36%) received a RT during a
median follow up period of 2,5 (1.4-4.1) years.
21 After a
median follow up period of 3.4 years, data on kidney fun
22 lant year in a cohort of 538 patients with a
median follow up period of 4.1 years.
23 d at least one episode of rejection during a
median follow-up period of 1,042 days (range, 336-1,896
24 18 patients diagnosed with TAVI-PVE during a
median follow-up period of 1.4 years (interquartile rang
25 During a
median follow-up period of 1.9 years (maximum, 5.0), sym
26 During a
median follow-up period of 10 (range: 0-49) years, there
27 During a
median follow-up period of 10 years (range, 5 to 28), 16
28 During a
median follow-up period of 10.2 years, VTE occurred in 4
29 During a
median follow-up period of 10.3 years after serum sample
30 During a
median follow-up period of 10.6 years (1994-2009), 395 c
31 During a
median follow-up period of 104.8 months (range, 3-317 mo
32 A
median follow-up period of 105.3 months (range, 12.7-286
33 During a
median follow-up period of 11 years, 12,089 CVD-related
34 f insulin resistance at baseline and after a
median follow-up period of 11.3 (range 7.3-13.4) years i
35 ings, and 59 safety communications) during a
median follow-up period of 11.7 years (interquartile ran
36 atients' clinical data were analyzed, with a
median follow-up period of 12 months (range, 2-31 months
37 Over a
median follow-up period of 12.6 years (range, 0.3-35.1 y
38 After a
median follow-up period of 13.2 years, 879 participants
39 During a
median follow-up period of 14 y (range, 3-21 y), 1347 de
40 After a
median follow-up period of 14.7 months, hepatotoxicity w
41 During the
median follow-up period of 16 years, there had been 307,
42 During a
median follow-up period of 16 years, there were 1621 CVD
43 Over a
median follow-up period of 17.9 months (interquartile ra
44 chieved a complete response relapsed after a
median follow-up period of 18 months.
45 eceived OHT, none required dialysis during a
median follow-up period of 18 months.
46 eported a positive HCV NAT result during the
median follow-up period of 182 (175-199) d post-LT.
47 During a
median follow-up period of 19 months, patients who were
48 During a
median follow-up period of 19 years (from 1971-1975 to 1
49 Over a
median follow-up period of 19 years, 158 of the 1690 HBV
50 During a
median follow-up period of 19.2 years, a total of 2,356
51 han a quarter of heart recipients during the
median follow-up period of 2 years.
52 Over a
median follow-up period of 2.1 years, 28% of patients tr
53 With a
median follow-up period of 2.2 years, the 2-year disease
54 al pancreatic cysts remained stable during a
median follow-up period of 2.2 years; however, in 27% of
55 cirrhosis, 61% (504 of 830) died during the
median follow-up period of 2.26 years.
56 rans with AKI, 31,146 deaths occurred over a
median follow-up period of 2.3 years.
57 40% to either dapagliflozin or placebo for a
median follow-up period of 2.3 years.
58 During a
median follow-up period of 2.4 years, 422 incident cases
59 L of which 371 (36%) received an RT during a
median follow-up period of 2.5 (1.4-4.1) years.
60 After the
median follow-up period of 2.5 years, patients receiving
61 For 2502 patients over a
median follow-up period of 2.5 years, there was no signi
62 f 960 subjects had an ischemic stroke over a
median follow-up period of 2.5 years.
63 a, with 2,397 (14.2%) receiving ADT during a
median follow-up period of 2.7 years (interquartile rang
64 Over a
median follow-up period of 2.7 years, there were no aort
65 During a
median follow-up period of 2.8 years, 13.8% experienced
66 losis patients, 9% of patients died within a
median follow-up period of 2.9 years: 342 (3.1%) during
67 ollowed up for a minimum of 6 months, with a
median follow-up period of 20 months.
68 Results of population-based data with over a
median follow-up period of 20 years showed that CKD inde
69 Over a
median follow-up period of 20.3 months (interquartile ra
70 rction, and congestive heart failure after a
median follow-up period of 20.9 months.
71 At a total
median follow-up period of 21 months, 31 patients had di
72 After a
median follow-up period of 21 months, no residual SCLs w
73 None have had a relapse of disease, with a
median follow-up period of 21 months.
74 During a
median follow-up period of 22 years (interquartile range
75 Over a
median follow-up period of 22.2 months, overall survival
76 Americans, and 671 deaths occurred during a
median follow-up period of 22.5 years (1987-2011).
77 After a
median follow-up period of 23 months (range, 9 to 40 mon
78 ogenous causes (3.4% of the cohort) during a
median follow-up period of 23.9 years.
79 During the
median follow-up period of 24 months, 144 (45%) patients
80 Over a
median follow-up period of 25 months, 1.3% (57 of 4347)
81 Over a
median follow-up period of 25 months, a primary end-poin
82 With a
median follow-up period of 25 months, the estimated 4-ye
83 Over a
median follow-up period of 25.5 months, no significant c
84 After a
median follow-up period of 26 months (interquartile rang
85 With a
median follow-up period of 26 months, the actuarial prob
86 During a
median follow-up period of 27 days (IQR 26-28), 31 (12%)
87 After a
median follow-up period of 28 months, 52 of the 115 pati
88 During a
median follow-up period of 28 years, there were 1123 CVD
89 Over a
median follow-up period of 28.5 months, 36 eyes (48.6%)
90 Over a
median follow-up period of 291 days (range, 180-466), 8
91 In a
median follow-up period of 3 y, an aggressive course of
92 0 patient-years) in the placebo group over a
median follow-up period of 3 years (hazard ratio adjuste
93 patients (9.3%) in the placebo group over a
median follow-up period of 3 years (hazard ratio, 0.99;
94 During a
median follow-up period of 3 years, exemestane was assoc
95 e study (average age 65 +/- 8 years), with a
median follow-up period of 3 years.
96 79 patients (2.15 IEps per patient) during a
median follow-up period of 3 years.
97 rst hospitalization (with alpha=0.03) over a
median follow-up period of 3 years.
98 6 PHIVA were included in the analysis with a
median follow-up period of 3.0 years, of whom 230 (7.2%)
99 6 PHIVA were included in the analysis with a
median follow-up period of 3.0 years, of whom 230 (7.2%)
100 nd 481 treatment-related AEs occurred over a
median follow-up period of 3.26 years.
101 n to coronary heart disease incidence over a
median follow-up period of 3.3 years among middle-aged m
102 During a
median follow-up period of 3.5 years, a first inappropri
103 After a
median follow-up period of 3.6 years, the composite end
104 During a
median follow-up period of 3.7 years, the primary end po
105 Over a
median follow-up period of 3.86 years, the HRs for CVD e
106 During a
median follow-up period of 3.9 years, participants who w
107 Over a
median follow-up period of 30 months, 789 patients (68%)
108 At a
median follow-up period of 30 months, the 3-year Kaplan-
109 During a
median follow-up period of 308 days, 61 MEs (4%) occurre
110 During the
median follow-up period of 31 (interquartile range 19;61
111 During a
median follow-up period of 31 months [IQR: 19-48 months]
112 The recurrence rate was 3.2% at a
median follow-up period of 32 months.
113 During a
median follow-up period of 33 years, there were 45,249 m
114 receiving placebo were well matched, with a
median follow-up period of 33.0 months (interquartile ra
115 During a
median follow-up period of 34 years (range 1-45), 101 me
116 At a
median follow-up period of 35 months, 1687 participants
117 tients were randomized and assessable with a
median follow-up period of 36 months; 61 received CSA an
118 During a
median follow-up period of 36.7 months, 1929 deaths occu
119 cardia) after the initial procedure during a
median follow-up period of 36.8 months.
120 996 men, and the recurrence-free group had a
median follow-up period of 37 months (range, 1 to 168 mo
121 During a
median follow-up period of 37.2 months, venous thromboem
122 After a
median follow-up period of 39.2 +/- 1.6 months (range: 0
123 8 deaths and 1 urgent transplantation over a
median follow-up period of 396 days.
124 During the
median follow-up period of 4 years, 25 patients (24.5%)
125 Over a
median follow-up period of 4 years, 6,741 (37.5%) develo
126 During a
median follow-up period of 4 years, 8% (21 of 259) exper
127 With a
median follow-up period of 4 years, the rate of freedom
128 regional radiotherapy are comparable with a
median follow-up period of 4 years.
129 ce interval (CI) 0.45-0.79, P = .001] over a
median follow-up period of 4.0 (inter-quartile range 2.2
130 After a
median follow-up period of 4.0 years after disease progr
131 During a
median follow-up period of 4.0 years, it was observed th
132 During the
median follow-up period of 4.1 years, the primary outcom
133 lant year in a cohort of 538 patients with a
median follow-up period of 4.1 years.
134 During a
median follow-up period of 4.2 years (range, 0-9 years),
135 of 326) experienced decompensation during a
median follow-up period of 4.22 years.
136 Over a
median follow-up period of 4.4 years in 7,040 patients (
137 in SAA-positive Parkinson's disease during a
median follow-up period of 4.5 years (IQR 2-9).
138 Over a
median follow-up period of 4.7 years, baseline statin us
139 regular Z line developed HGD or EAC during a
median follow-up period of 4.8 years (interquartile rang
140 During a
median follow-up period of 4.8 years, the time until dev
141 dence interval, 0.88 to 1.06; P=0.43) over a
median follow-up period of 4.8 years.
142 After a
median follow-up period of 4.9 years, the 2-year estimat
143 In a
median follow-up period of 42 months, 55 (19%) individua
144 this cohort, 68 deaths were observed over a
median follow-up period of 42 months.
145 In a
median follow-up period of 43 months (interquartile rang
146 Over a
median follow-up period of 43 months (interquartile rang
147 With a
median follow-up period of 45 months, more than 70% of p
148 Over a
median follow-up period of 45.5 months, 269 patients (33
149 dy, and 93 mammograms were obtained during a
median follow-up period of 46 months (range, 22-58 month
150 With a
median follow-up period of 46 months, the 3-year overall
151 Over a
median follow-up period of 46 years, 508 men developed h
152 At a
median follow-up period of 46.6 months (range, 10.7 to 9
153 During a
median follow-up period of 47.2 months, advanced colorec
154 During a
median follow-up period of 48 (45-52) months, 225 patien
155 Over a
median follow-up period of 5 months (mean, 6 months; ran
156 ath or cardiovascular hospitalization over a
median follow-up period of 5 years (with a range of 4 to
157 During a
median follow-up period of 5 years, treatment was succes
158 vastatin 40 mg/day or matching placebo for a
median follow-up period of 5 years.
159 After a
median follow-up period of 5.1 years, 372 subjects exper
160 Over a
median follow-up period of 5.1 years, dementia developed
161 During a
median follow-up period of 5.2 years, 203 patients died
162 a significant predictor of diabetes after a
median follow-up period of 5.2 years, and each factor re
163 37 (53%) patients experienced MACE during a
median follow-up period of 5.3 (interquartile range, 1.8
164 Over a
median follow-up period of 5.4 years, 969 participants (
165 Over a
median follow-up period of 5.63 years, patients with T2D
166 cedures approximately every 15 months over a
median follow-up period of 5.7 years (through September
167 After a
median follow-up period of 5.7 years, 10,766 subjects ha
168 Analysis of CEA anatomic durability during a
median follow-up period of 5.9 years identified a 7.7% f
169 In a
median follow-up period of 50 months, REn outcomes were
170 With a
median follow-up period of 50 months, the 5-year CFS rat
171 mpts from 179 centres in 23 countries with a
median follow-up period of 51.1 months (IQR: 21.6-64.2).
172 Over a
median follow-up period of 51.2 months (interquartile ra
173 During a
median follow-up period of 52 days (IQR: 16-66 days), ac
174 ents who underwent an OVHR with mesh, with a
median follow-up period of 56 months (range, 1-156 month
175 surgery among 4036 patients with CD, with a
median follow-up period of 58 months.
176 After a
median follow-up period of 58.2 months, 668 patients (50
177 in the surgery group was 8.5% (6/70) over a
median follow-up period of 59 +/- 2.7 months for the PDT
178 (60%) no longer required opioid therapy at a
median follow-up period of 6 months.
179 After a
median follow-up period of 6 years (IQR: 2.3 to 13.9 yea
180 Over a
median follow-up period of 6.0 years, we recorded 3 seve
181 th 3,871 patients enrolled onto the trial, a
median follow-up period of 6.1 years, and 437 RFS events
182 ardiovascular disease (4476 subjects) over a
median follow-up period of 6.2 years.
183 During a
median follow-up period of 6.3 years, the cumulative inc
184 At a
median follow-up period of 6.4 years, the median EFS was
185 infectious disease deaths were seen during a
median follow-up period of 6.4 years.
186 articipants 73 years of age or older, with a
median follow-up period of 6.5 years, and 33 incident ca
187 Over a
median follow-up period of 6.5 years, we identified 2593
188 were not diagnosed with lung cancer after a
median follow-up period of 6.6 years.
189 Over a
median follow-up period of 6.7 years, 106 patients died.
190 During a
median follow-up period of 6.8 years, there were 52 deat
191 In total, 9,965 patients with a
median follow-up period of 6.99 years (25th to 75th perc
192 At a
median follow-up period of 60 months (range, 10 to 180 m
193 n in our study did not develop LSIL within a
median follow-up period of 60 months.
194 tions in circulating fibrocyte counts over a
median follow-up period of 614 days.
195 After a
median follow-up period of 67.6 months, the primary outc
196 Cardiovascular events were recorded over a
median follow-up period of 7.1 years (Q1 = 3.6 years, Q2
197 atients, 1,825 were women (40%), and after a
median follow-up period of 7.2 years, 344 patients (7.5%
198 of controls were diagnosed with AF during a
median follow-up period of 7.2 years.
199 During a
median follow-up period of 7.3 years, 10,634 kidney canc
200 After a
median follow-up period of 7.4 months, the median progre
201 During a
median follow-up period of 7.4 years, 1212 (3.1%) partic
202 a total of 210 participants (6.2%) during a
median follow-up period of 7.8 years.
203 ohort free of clinical heart disease, over a
median follow-up period of 7.9 years.
204 Over a
median follow-up period of 73 months, 238 patients died
205 After a
median follow-up period of 75 months, 63 patients (74%)
206 998, 18 patients (36%+/-13%) survived with a
median follow-up period of 767 days (range, 602 to 1,127
207 ects developed chronic pancreatitis during a
median follow-up period of 78 months (interquartile rang
208 ree of disease after salvage therapy, with a
median follow-up period of 79 months.
209 After a
median follow-up period of 8 y from age 26 y, we found t
210 After a
median follow-up period of 8.0 years (IQR: 4.6-10.9 year
211 During a
median follow-up period of 8.0 years (through August 24,
212 During a
median follow-up period of 8.2 years, there were 285 dea
213 With a
median follow-up period of 8.3 years (range, 1.5 to 22.1
214 During a
median follow-up period of 8.4 years, 1,603 women and 95
215 Over a
median follow-up period of 8.6 years, overall mortality
216 During a
median follow-up period of 8.8 (IQR: 4.8-13.3) years, in
217 Over a
median follow-up period of 81 months, 1097 individuals p
218 deaths and 5 urgent transplantations over a
median follow-up period of 841 days.
219 During a
median follow-up period of 890 days (interquartile range
220 rt failure, and cardiovascular death) over a
median follow-up period of 9 years were assessed.
221 After a
median follow-up period of 9.1 y, we recorded 6,595 deat
222 ulticenter international cohort study with a
median follow-up period of 9.2 years was conducted in 5
223 During a
median follow-up period of 9.3 years, 227 women (9.9% of
224 During a
median follow-up period of 9.7 years, 505 diabetes cases
225 After a
median follow-up period of 920 days, 46% of the original
226 Over a
median follow-up period of eight years, dementia develop
227 between November 2001 and July 2007, with a
median follow-up period of more than 9 years.
228 The
median follow-up period of surviving patients was 4.1 ye
229 l myocardial infarction [MI] in 27) during a
median follow-up period of three years.
230 After
median follow-up periods of 58 and 89 months (types 1 an
231 Data were collected over
median follow-up periods of 889 days (interquartile rang
232 In the 2.7 year
median follow-up period,
patients without obstructive CA
233 as a negative study in that after a 7.6-year
median follow-up period,
there were no statistically sig
234 The
median follow up period was 23 months.
235 The
median follow-up period was 1 year (range, 1-10 years).
236 The
median follow-up period was 1.4 (interquartile range: 0.
237 The
median follow-up period was 1.6 years for INSPIRE and 2.
238 The
median follow-up period was 10.3 years.
239 The
median follow-up period was 11 years (IQR, 7-19 years; r
240 3 months (range, 0.25-12.00 months), and the
median follow-up period was 12 months (range, 1-36 month
241 At the data cutoff (Aug 7, 2019), the
median follow-up period was 12.9 months (IQR 6.2-22.9).
242 The
median follow-up period was 15 months.
243 recipient age was 63.2 (16.6) years and the
median follow-up period was 17 months (interquartile ran
244 The
median follow-up period was 186 weeks (interquartile ran
245 The
median follow-up period was 2.2 years (interquartile ran
246 The
median follow-up period was 2.4 years.
247 The
median follow-up period was 2.5 years.
248 The
median follow-up period was 2.67 years.
249 The
median follow-up period was 20.6 months.
250 The
median follow-up period was 27 mo (1-108 mo).
251 The
median follow-up period was 27 months.
252 The
median follow-up period was 28.9 months.
253 The
median follow-up period was 3.01 years.
254 The
median follow-up period was 3.21 years.
255 The
median follow-up period was 3.4 years.
256 s (interquartile range 2.7-5 years), and the
median follow-up period was 3.75 years.
257 The
median follow-up period was 3.8 years.
258 The
median follow-up period was 30 months.
259 The
median follow-up period was 32 months (range, 5-114).
260 The
median follow-up period was 37 months.
261 The
median follow-up period was 38 mo (95% confidence interv
262 The
median follow-up period was 4 years (range, 0 to 23).
263 The
median follow-up period was 4.0 years.
264 The
median follow-up period was 4.06 years.
265 The
median follow-up period was 4.1 years.
266 The
median follow-up period was 4.6 years for mortality and
267 The
median follow-up period was 4.7 years.
268 The
median follow-up period was 4.8 y.
269 The
median follow-up period was 4.8 years.
270 patients were included in the study and the
median follow-up period was 41 months.
271 The
median follow-up period was 43 months.
272 The
median follow-up period was 5 +/- 3.9 years (7846 patien
273 The
median follow-up period was 50.2 months.
274 The
median follow-up period was 51.2 months.
275 The
median follow-up period was 52 months.
276 The
median follow-up period was 53 months.
277 Median follow-up period was 6 months (IQR: 1.5 to 18 mon
278 The
median follow-up period was 6.2 years.
279 Median follow-up period was 61.9 months.
280 The
median follow-up period was 62 months.
281 The
median follow-up period was 620 days.
282 The
median follow-up period was 69 months (range, 6-126 mont
283 classified 6 months after presentation, the
median follow-up period was 7.2 years (quartiles at 6.2
284 The
median follow-up period was 7.2 years.
285 The
median follow-up period was 7.3 years.
286 8 months (range 4 months-19 years), and the
median follow-up period was 8 years (range 3 months-18 y
287 The
median follow-up period was 8.1 months (IQR, 4.2-13.9).
288 The
median follow-up period was 8.2 years.
289 Of 1,608,540 children, the
median follow-up period was 8.41 years (interquartile ra
290 total follow-up of 162,974 person-years (the
median follow-up period was 8.5 years).
291 The
median follow-up period was 84 months (range 32-106 mont
292 The
median follow-up period was 9.1 years.
293 The
median follow-up period was 9.3 years (range 0.1 to 23.6
294 The
median follow-up period was 9.4 months (IQR 4.2-20.6).
295 The
median follow-up period was 9.4 years.
296 The
median follow-up period was 9.8 years.
297 The
median follow-up period was of 34 mo (15-69 mo).
298 The
median follow-up period was ~15 years.
299 The prognosis of eyes over a 5-year (
median) follow-up period was determined based on FECD pr
300 The
median follow-up periods were 28.4 and 27.4 mo for i-PET